NEW YORK, March 2, 2015 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Bionomics Ltd. (ASX: BNO; OTCQX: BNOEF), a global biopharmaceutical company developing better treatments for cancer and central nervous system disorders, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.
Bionomics begins trading today on OTCQX under the symbol "BNOEF." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased to welcome Bionomic to OTCQX," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "Trading on OTCQX will broaden Bionomics' exposure to U.S. investors through transparent trading and broad distribution of its news and financial disclosure in the U.S. We look forward to supporting Bionomics and its shareholders as the company continues to expand its presence in the U.S. market and globally."
"We have seen growing interest from U.S. investors in Bionomics joining the OTCQX marketplace – a logical move that will provide new opportunities for the company," said Dr. Deborah Rathjen, Bionomics' CEO and Managing Director.
Cowen and Company, LLC serves as Bionomics' Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements.
Bionomics discovers and develops biopharmaceuticals for the treatment of cancer, immune diseases and disorders of the central nervous system in Australia, France and the United States. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumors.
Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace; OTCQB®, The Venture Marketplace; and OTC Pink®, The Open Marketplace. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, email@example.com
SOURCE OTC Markets Group Inc.